Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
2 Himanshu Baid (Managing Director), Rahul Gautam (President, Strategy and Corporate Development)
Analysts
6 Bhavya Gandhi (Bajaj Alternate Investment Managers Ltd), Bharat C. Shah (BCS Capital Ideas Private Limited), Deepak Ramesh (Sundaram Finance Ltd), Girish Jain (KJMC Capital), Rashmi Shetty (Dolat Capital), Sidharth Negandhi (Chanakya Wealth Creation)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Standalone Revenue | ₹431 crores | +12.3% YoY; domestic ₹146 crores (+16.2%), international ₹281.8 crores (+10%) |
| Consolidated Revenue | ₹525 crores | +30.3% YoY; ₹72.3 crores from acquisitions; organic ₹453.1 crores (+12.4%) |
| Revenue Mix - Infusion Therapy | ₹259.2 crores | +11.1% YoY; domestic infusion grew 20%+ led by higher-value products |
| Revenue Mix - Orthopedics | ₹49.2 crores | Reflects CTF consolidation |
| Revenue Mix - Cardiology | ₹28.6 crores | Up from ₹2.9 crores; Penrocare acquisition + domestic scale-up |
| Revenue Mix - Renal | ₹43.2 crores | Degrew 3.8% YoY; Chinese price dumping, conscious choice to raise prices rather than defend volume |
| Revenue Mix - Others | ₹149 crores | +18.5% YoY |
| Standalone Gross Margin | 71.45% | Improved on better product mix, price hikes, inventory gains; expects normalization to 68-69% |
| Standalone EBITDA | ₹120.8 crores | +18.8% YoY; margin 28% vs guided 25-27%; employee cost rose 29% on 35% Haryana wage hike |
| Consolidated Gross Margin | 73.4% | Up 495 bps YoY; higher-margin acquired businesses lifted group margin |
| Consolidated EBITDA | ₹126.7 crores | +17.7% YoY; margin 24.1%, within guided 23-25% range |
| Europe Revenue | ₹187.3 crores | +43.8% reported / +17.6% organic; recovery from last year's laggard performance |
| Rest of World Revenue | — | +30.3% reported / +4.0% organic; Middle East degrew 32% on logistics bottlenecks |
| Cash Position | ~₹855 crores | Reserved for strategic initiatives (inorganic + capex) |
| Asset Turnover | 1.2-1.4x | Historical range expected to continue as new plants scale |
| Gross Debt | ~₹250 crores working capital + €9M (CTF) | Standalone has no long-term debt; CTF annual repayment €1.5-2M |
Geographic & Segment Commentary
- Domestic India: Grew 16.2% to ₹146 crores; infusion grew 20%+, cardiology and critical care contributed meaningfully; renal faced Chinese dumping pressure with conscious price-over-volume strategy; stronger brand recall across corporate hospitals enables deeper product penetration.
- Europe: Grew 43.8% to ₹187.3 crores (17.6% organically); rebound driven by new customer onboarding and recovery from last year's sluggishness; company present directly only in Italy, targeting 3-4 direct geographies.
- Middle East / Rest of World: ROW grew 4% organically; Middle East degrew 32% due to shipping disruptions and container shortages despite intact demand; order book strong, products piling at ports awaiting vessel availability.
- Renal: Degrew 3.8% to ₹43.2 crores; anti-dumping investigation initiated by Government of India against Chinese and Malaysian dialyzer imports with claimed injury margin of 20%; new head of renal business (Abhinav Houda) appointed to drive turnaround; management targets 15-18% growth by year-end.
- Cardiology: Scaled from ₹2.9 crores to ₹28.6 crores on Penrocare acquisition and domestic ramp-up; 25-30 products expected annually with CE marking pipeline; Government grant of ₹3.3 crores for clinical studies of import-substitution devices.
- Orthopedics: ₹49.2 crores in Q1 from CTF consolidation; Faridabad plant (operational by March 2027) to expand orthopedics and transfusion capacity.
Company-Specific & Strategic Commentary
- PolyMed 3.0 ("Ascent") Strategic Vision: Target to double revenue by FY30 (~18% CAGR over 4 years) via organic and inorganic expansion, technology scale-up in high-complexity verticals, and deepening direct customer access globally; ~80% organic, ~20% inorganic mix expected; leadership reinforced with Indraneer Mukherjee (CEO India & APAC, joined June 1), Leonardo Rocca (CEO Brazil, joined August 1), and Abhinav Houda (Head of Renal).
- Inorganic Growth Pipeline: ₹855 crores cash reserve allocated for acquisitions in cardiology, oncology, orthopedics adjacent technologies, plus capex for two new plants; small Brazilian acquisition completed; funds allocated for direct sales presence expansion in Brazil.
- Anti-Dumping Filing: Government initiated investigation into dialyzer imports from China and Malaysia; injury margin claim of 20%; zero-duty imports via ASEAN FTA flagged to Minister J.P. Nadda; decision expected within the year.
- Portfolio Diversification: Vascular segment dependence reduced to ~50% of revenue; shift toward high-technology, platform-based businesses (dialysis machines, IVL therapy equipment); 390 patents held globally; 25 new CE-marking products in pipeline over next 3-4 months.
- Capacity Expansion: Faridabad/Palwal facility (orthopedics, transfusion, infusion expansion) operational by March 2027; Noida facility (cardiology) commercially live Q1 FY28; FY27 capex guidance ₹200-225 crores.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Consolidated Revenue (FY27) | ₹2,300-2,400 crores (maintained) | Includes full-year consolidation of Pendrocare and CTF; Q1 tends to be lowest quarter historically |
| Standalone Revenue (FY27) | ₹1,900-2,000 crores (maintained) | Domestic expected +20%+, international +15%+; Q2 onwards momentum accelerates |
| Standalone EBITDA Margin (FY27) | 25-27% | Q1 delivered 28% on price hikes and inventory gains; expected to settle in higher end of range |
| Consolidated EBITDA Margin (FY27) | 23-25% | Acquired entities carry higher cost structures while scaling; Q1 at 24.1% |
| Consolidated Gross Margin (FY27) | ~71-72% | Pendrocare and CTF operate at higher gross margins, lifting group profile |
| Standalone Gross Margin (FY27) | 67-69% | Normalization from Q1's 71.45% as inventory gains and one-off price benefits fade |
| FY27 Capex | ₹200-225 crores | Two new plants under construction (Faridabad, Noida) |
| Renal Revenue Growth (FY27) | 15-18% exit rate | Anti-dumping protection + new leadership; Q1 degrew 3.8% |
| PolyMed 3.0 Revenue Target (FY30) | 2x FY26 revenue | ~18% CAGR; 80% organic/20% inorganic; subsidiary growth mid-teens aspiration with synergies |
| Asset Turns | 1.2-1.4x | Expected to sustain on new capex |
Risks & Constraints
| Risk | Context |
|---|---|
| Middle East Shipping Disruption | Continued 32% degrowth in Middle East due to container shortages and disrupted shipping schedules despite intact demand; orders piling at ports; management hopeful of easing within coming weeks but cannot commit to a timeline; once resolved, >20-25% growth expected from the region. |
| US Tariff Uncertainty | Current duty at 10% with manageable exposure (₹3.5-4 crores US exports); however, fluid situation — 100% tariff scenario would materially impact competitiveness; management monitoring closely. |
| Raw Material / Logistic Cost Inflation | Crude oil prices and freight costs up 2-3x in last six months; management believes peak has passed if crude stays range-bound, but logistics cost normalization needed for India to remain export-competitive. |
| Chinese Price Dumping in Renal | Chinese dialyzer imports via ASEAN FTA at zero duty pressured pricing; management chose price rationalization over volume defense, resulting in 3.8% Q1 degrowth; anti-dumping investigation with 20% injury margin claim may provide relief by year-end. |
| Regulatory Timelines for Synergies | Cross-selling and manufacturing transfer for Pendrocare/CTF require CDSCO approvals; benefits not visible until FY28; regulatory pathway for new cardiology products takes 2-3 years with clinical studies. |
| Haryana Wage Inflation | 35% minimum wage increase effective April 2026 drove ~29% rise in employee costs in Q1; partially absorbed by price hikes, but structural cost pressure persists. |
| Geopolitical Uncertainty | Daily changing situation in Middle East creates unpredictability across shipping, insurance, and customer payment cycles; working capital cycle sticky at ~140 days. |
Q&A Highlights
Revenue Guidance Attainability
- Question: How will standalone revenue reach ₹1,900-2,000 crores given Q1's ~12% growth rate? (Bhavya Gandhi)
- Answer: Q1 is historically the lowest quarter; price hikes taken at start of year; momentum builds from Q2 onwards as the pace of order intake accelerates. (Rahul Gautam)
Use of ₹855 Crore Cash Reserve
- Question: What is the deployment plan for the cash balance? (Bhavya Gandhi)
- Answer: Funds allocated across organic capex (two new plants), Brazilian direct-sales expansion, and inorganic opportunities in cardiology, oncology, and orthopedics adjacent technologies; asset turns expected at 1.2-1.4x. (Himanshu Baid, Rahul Gautam)
India Growth Drivers and Middle East Disruption
- Question: What drove India growth ex-renal, and has Middle East shipping resumed? (Sidharth Negandhi)
- Answer: Domestic infusion grew 20%+, cardiology and critical care contributed meaningfully. Shipping remains disrupted — containers hard to source for Middle East ports; orders are piling at factories; demand intact and expected to resume with logistics normalization. (Rahul Gautam, Himanshu Baid)
Acquisition Integration and Synergies
- Question: Are cross-sell synergies visible yet, and is manufacturing moving to India? (Sidharth Negandhi)
- Answer: Integration progressing well; cost, R&D and sales-velocity synergies identified with a dedicated group tracking; manufacturing transfer to India at regulatory approval stage; cross-sell benefits expected visible from FY28. (Rahul Gautam)
PolyMed 3.0 Doubling Target Assumptions
- Question: Is ~18% CAGR for 4 years the right math, and what margin profile should be assumed? (Bharat C. Shah)
- Answer: 80% organic / 20% inorganic split; standalone business growing faster than subsidiaries; margins should hold at similar levels near-term given reinvestment focus, with improvement potential as scale builds. (Himanshu Baid, Rahul Gautam)
Pendra Care/CTF Growth and Consolidated Margins
- Question: Are acquired entities showing growth, and will consolidated EBITDA margins expand? (Rashmi Shetty)
- Answer: Pendra Care is not growing due to ~20% Middle East over-indexation; CTF growing mid-high single digits; standalone assets can grow high single digits, increasing toward mid-teens with synergies; no formal margin guidance beyond current 23-25% range. (Rahul Gautam)
Gross Margin Trajectory
- Question: Will Q1's gross margin hold, or normalize? (Deepak Ramesh)
- Answer: Standalone gross margin should be 67-69%; consolidated ~71-72% given acquired entities' higher gross margins; Q1's 71.45% was aided by inventory gains and price hikes. (Himanshu Baid)
US Tariff Exposure
- Question: What is the FY27 US tariff impact? (Unidentified participant)
- Answer: Current duty at 10%; US exposure limited to ₹3.5-4 crores annually; manageable unless tariff regime changes significantly. (Himanshu Baid)
Operating Leverage Potential
- Question: How much operating leverage can play out over 3-4 years? (Bhavya Gandhi)
- Answer: Material portion of employee cost is blue-collar (variable portion); rest fixed with productivity gains; no exact fixed/variable split available on call, to share offline. (Rahul Gautam)
New Therapy Entry and Market Coverage
- Question: Are there plans to enter new therapy areas or expand within existing ones? (Girish Jain)
- Answer: Existing therapies are new (2 years for cardiology); regulatory timelines (2-3 years for Class C devices) mean focus is on current portfolio; several untapped therapy areas exist but no near-term new entries; work happening in pipeline not yet disclosed. (Himanshu Baid)
Europe Recovery and Working Capital
- Question: Is Europe's bounce-back sustainable, and will cash conversion improve? (Girish Jain)
- Answer: Europe grew 17.6% organically with new customer additions; cash conversion cycle stable at ~140 days, pressured by extended shipping times during conflict; improvement expected as geopolitical situation normalizes. (Himanshu Baid, Rahul Gautam)
New Facility Timelines
- Question: When will the new facilities be operational, and which therapies? (Girish Jain)
- Answer: Faridabad/Palwal facility (orthopedics, transfusion, infusion expansion) live by March 2027; Noida facility (cardiology) commercially live in Q1 FY28. (Himanshu Baid)
Key Takeaway
Poly Medicure delivered a resilient Q1 FY27 with standalone revenue of ₹431 crores (+12.3%) and consolidated revenue of ₹525 crores (+30.3%), with acquisitions contributing ₹72.3 crores. EBITDA margins outperformed — 28% standalone and 24.1% consolidated — aided by price hikes, product mix, and inventory gains, though management expects normalization to 67-69% gross margins. The company launched PolyMed 3.0 ("Ascent" phase), targeting revenue doubling by FY30 through an 80/20 organic-inorganic mix, supported by ₹855 crores cash, new leadership appointments for India/APAC and Brazil, and government-backed anti-dumping protection for dialyzers. Europe returned to growth (17.6% organic) after last year's weakness, while Middle East remains constrained by shipping disruptions with strong pent-up order book. Key watchpoints include US tariff fluidity, logistic cost pressures, Chinese pricing competition in renal, and the pace of Pendrocare/CTF synergy realization, expected to surface from FY28. Management maintains FY27 revenue guidance of ₹2,300-2,400 crores consolidated and ₹1,900-2,000 crores standalone, with capex of ₹200-225 crores across two new plants.